GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zentalis Pharmaceuticals
Zentalis, an oncology biotech, shares reflect the potential of its targeted therapies. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Breast cancer
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing small-molecule cancer drugs, including WEE1 inhibitors. We consider it a key focus area in the Breast Cancer sector. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Zentalis Pharmaceuticals is an oncology company developing a new class of drugs called WEE1 inhibitors for the treatment of various types of cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Zentalis shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ZNTL - Daily change in the company's share price Zentalis Pharmaceuticals
For Zentalis Pharmaceuticals, a company focused on oncology, the daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Breast cancer
Zentalis Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ZNTL's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Zentalis Pharmaceuticals is a biotech company focused on developing drugs for the treatment of breast cancer and other oncological diseases. Its shares are driven by news of clinical successes, and their high volatility is part of a broader trend in which scientific breakthroughs shape market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zentalis Pharmaceuticals
Zentalis Pharmaceuticals' year-to-date performance is a story of developing a new generation of targeted cancer therapies. Its 12-month market cap is entirely dependent on clinical trial data for its WEE1 and BCL-2 inhibitors. Success in this area could offer new options for patients with difficult-to-treat tumors.
Annual dynamics of market capitalization of the market segment - Breast cancer
Zentalis Pharmaceuticals, Inc. is a clinical-stage biotech company developing a new class of drugs for the treatment of cancer. Its stock price is entirely dependent on the results of clinical trials. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zentalis is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cancer drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is an oncology company developing small-molecule drugs. Its monthly performance is driven by news from its clinical programs. Positive data on the efficacy of its WEE1 inhibitors, presented at medical conferences, is generating significant investor interest.
Monthly dynamics of market capitalization of the market segment - Breast cancer
Zentalis Pharmaceuticals is a clinical-stage oncology company developing small-molecule drugs for the treatment of various cancers, with a particular focus on WEE1 inhibitors. The chart below shows the dynamics of the biotech sector, where targeted therapy remains a key focus in the fight against cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zentalis Pharmaceuticals is a biotech company focused on developing cancer drugs. Its shares, like all companies in this sector, are completely uncorrelated with the market. Their price is a bet on the success of scientific research, and any news about the company's drugs can dramatically change its value.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, a biopharmaceutical company focused on breast cancer, exhibits high volatility. Its weekly stock price reflects news about clinical trials, drug efficacy data, and regulatory decisions. The chart reflects the hopes and risks in the fight against cancer.
Weekly dynamics of market capitalization of the market segment - Breast cancer
Zentalis Pharmaceuticals develops targeted cancer drugs. In biotech, news is everything. This chart will show whether weekly stock price fluctuations are driven by company news or by overall sector trends. This is key to understanding whether Zentalis is riding the wave or the tide in the world of oncology innovation.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Zentalis Pharmaceuticals is a clinical-stage biotech whose future depends on the success of cancer research. Its shares exist in a world of their own, where drug news trumps macroeconomics. The chart clearly shows that Zentalis's performance is largely uncorrelated with the market, moving on its own unique drivers.
Market capitalization of the company, segment and market as a whole
ZNTL - Market capitalization of the company Zentalis Pharmaceuticals
Zentalis's market capitalization isn't a business valuation, but a financial electrocardiograph of its clinical trials. Every peak and trough on this chart is a direct investor reaction to news about its cancer drugs. Its volatility reflects the binary nature of biotech: the hope of a breakthrough or the risk of failure, where data decides everything.
ZNTL - Share of the company's market capitalization Zentalis Pharmaceuticals within the market segment - Breast cancer
Zentalis's market share in the biotech sector reflects its status as a company focused on developing highly specialized cancer treatments. Its market weight is determined not by its current dominance, but solely by the potential of its clinical programs, which are closely monitored by the entire investment community.
Market capitalization of the market segment - Breast cancer
Zentalis Pharmaceuticals is at the forefront of the fight against breast cancer. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the flow of investment, faith in scientific breakthroughs, and the enormous hopes of patients and doctors for new, more effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Zentalis Pharmaceuticals is a biotech company developing small-molecule drugs for cancer treatment. Its market capitalization reflects the potential of its oncology research. The chart below shows the global economic weight of companies at the forefront of the fight against cancer.
Book value capitalization of the company, segment and market as a whole
ZNTL - Book value capitalization of the company Zentalis Pharmaceuticals
For Zentalis, a biopharmaceutical company, the book value chart isn't about plants, but about financial headroom. The line below tracks capital and lab equipment—resources for conducting expensive clinical trials. Its dynamics visualize the cash burn that fuels the engine of scientific discovery.
ZNTL - Share of the company's book capitalization Zentalis Pharmaceuticals within the market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech company focused on cancer treatment. Its primary asset is a portfolio of promising molecules and clinical trial data. Its tangible asset ratio will be minimal, as is typical for R&D companies whose value lies in intellectual property rather than manufacturing facilities.
Market segment balance sheet capitalization - Breast cancer
Zentalis Pharmaceuticals is a biotech company whose capital lies not in machinery, but in cutting-edge science. It fights cancer at the molecular level using a "light" model focused on R&D. Is this focus on intelligence the norm for the entire pharmaceutical industry? The chart below reveals the true material "weight" of the entire sector.
Book value of all companies included in the broad market index - GURU.Markets
Zentalis Pharmaceuticals' balance sheet is the financial spearhead of the attack on breast cancer. Its assets are not machine tools, but capital invested in clinical trials and patents for targeted drugs. The book value chart shows how much resources are concentrated on this important front in the fight against cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a biotech company focused on developing new cancer drugs. Its book value is primarily derived from cash flow from research. Its market capitalization represents investors' collective bet on the scientific success of its pipeline. The chart shows how the company's valuation fluctuates based on lab and clinical trial news.
Market to book capitalization ratio in a market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech whose value lies in its cancer drug pipeline, not its labs. This chart clearly demonstrates the enormous premium investors are placing on its scientific potential. Its market valuation is several times higher than its book value, reflecting expectations for the future commercial success of its drugs.
Market to book capitalization ratio for the market as a whole
Zentalis Pharmaceuticals is a biotech company fighting cancer at the molecular level. This chart clearly demonstrates how the market values science and hope. Its market capitalization is not tied to the value of its laboratories, but rather reflects investors' bets on the success of its clinical trials and the life-saving potential of future drugs.
Debts of the company, segment and market as a whole
ZNTL - Company debts Zentalis Pharmaceuticals
Zentalis, a clinical-stage pharmaceutical company focused on oncology, is using its raised capital to advance its portfolio of innovative small-molecule drugs through the expensive and time-consuming clinical development process.
Market segment debts - Breast cancer
Zentalis Pharmaceuticals is a biotech company focused on developing cancer drugs. Their operations require massive investments in clinical research long before they can turn a profit. This chart illustrates the financial norms of the pharmaceutical industry, which illustrates how Zentalis and other R&D companies are raising capital to finance their long and risky battle against cancer.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is pursuing expensive cancer drug development. This chart shows the proportion of debt financing for this research, compared to equity. For a biotech company, this is a key indicator: it reflects both the lenders' confidence in its drugs and the risks if the trials don't meet investors' expectations.
Market segment debt to market segment book capitalization - Breast cancer
Developing targeted cancer drugs, as Zentalis does, requires colossal funding for years to come. This chart shows how the biotech sector as a whole uses debt for its research. It allows us to appreciate how Zentalis's financial model, which is currently in clinical trials, differs from the overall strategy in this research-intensive industry.
Debt to book value of all companies in the market
Zentalis Pharmaceuticals is challenging cancer, which requires colossal investments in research. Drug development is a long and costly process, often financed by debt. This chart allows us to assess how the company's debt load, taken on for future breakthroughs, compares to the overall market appetite for risk and debt.
P/E of the company, segment and market as a whole
P/E - Zentalis Pharmaceuticals
This metric for Zentalis Pharmaceuticals, a biopharmaceutical company focused on cancer treatment, reflects investor expectations. Since the company is in clinical development and may not generate consistent profits, its value is determined by the potential of its scientific research. The chart reflects the market's confidence in the future success of its drugs, rather than an assessment of its current financial performance.
P/E of the market segment - Breast cancer
This metric represents the average valuation for the biotech sector in which Zentalis operates. In this industry, where most companies are in the non-revenue-producing research stage, the average valuation reflects the overall level of investor optimism. It serves as a barometer of market confidence in scientific breakthroughs for the entire oncology segment.
P/E of the market as a whole
Zentalis Pharmaceuticals develops targeted drugs for cancer treatment, and its value depends almost entirely on the success of clinical trials. This chart reflects investors' overall risk appetite. During periods of market optimism, it's easier to fund long-term research projects. This helps us understand whether Zentalis is benefiting from the overall trend or whether its shares are driven solely by lab news.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zentalis Pharmaceuticals
Zentalis Pharmaceuticals focuses on developing small-molecule cancer therapies, particularly inhibitors for breast cancer. The company's future depends on the success of clinical trials and regulatory approval. This timeline reflects investor expectations regarding the scientific breakthrough and commercial potential of its targeted therapies in the highly competitive oncology field.
%20P%2FE%20Zentalis%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zentalis-Pharmaceuticals&v=1772696717936 "Chart of the company's future (projected) P/E Zentalis Pharmaceuticals")
Future (projected) P/E of the market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for cancer treatment. The company's future, like many in the sector, hinges on the success of clinical trials. This chart reflects general profitability expectations in the biotech industry, allowing us to assess how highly the market values Zentalis's scientific potential compared to its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772696717945 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
For Zentalis Pharmaceuticals, which develops targeted cancer drugs, the overall market sentiment shown in this chart is crucial. High investor optimism facilitates raising the significant capital needed to conduct expensive clinical trials. The company's success depends on the market's faith in science and willingness to finance long-term, high-risk projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772696717974 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biotechnology company focused on developing cancer drugs. This chart reflects the financial costs of research and conducting expensive clinical trials. Future profitability depends entirely on the successful results of these trials and subsequent regulatory approval of the drugs.
Profit of companies in the market segment - Breast cancer
Beam Global is a charging infrastructure innovator building off-grid solar power stations for electric vehicles. Profitability in this sector is closely tied to the pace of transport electrification and the scale of government subsidies. This chart reflects the dynamics of a young industry, where aggressive growth and investment in the future currently outweigh current profitability.
Overall market profit
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for the treatment of cancer, particularly breast cancer. Its future depends on success in clinical trials. The overall economic situation, reflected in this chart, affects the availability of capital to finance such long-term and socially significant research projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a biotechnology company focused on developing small-molecule cancer drugs, specifically WEE1 inhibitors. Its revenue forecast is entirely dependent on the success of clinical trials and future drug approvals. This chart reflects analyst expectations regarding Zentalis's scientific progress and its ability to bring new treatments to market.
%20profit%20of%20the%20company%20Zentalis%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zentalis-Pharmaceuticals&v=1772696718034 "Graph of future (projected) profit of the company Zentalis Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Breast cancer
Zentalis Pharmaceuticals is leading a targeted attack on breast cancer by developing innovative small-molecule drugs. The company's success depends on a breakthrough in a specific scientific niche. This chart shows overall profitability forecasts for the entire oncology sector. It allows one to assess how Zentalis's risky but potentially breakthrough strategy compares to overall industry expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772696718045 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
Zentalis Pharmaceuticals, which focuses on breast cancer treatments, operates in a sector whose revenues are less dependent on general economic cycles. This chart, which displays aggregate market revenue forecasts, is important for assessing the overall investment climate, which may impact the availability of capital for biotech R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772696718062 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for the treatment of cancer, particularly breast cancer. Without stable sales revenue, its valuation, as shown in the chart, depends entirely on investor confidence in its scientific platform and the success of clinical trials. The valuation reflects expectations for a breakthrough in oncology.
P/S market segment - Breast cancer
Zentalis Pharmaceuticals is a biotechnology company developing small-molecule drugs for the treatment of cancer. While the company is in the clinical stage, its revenue is promising and depends on the success of its research. This chart shows average valuations in the oncology sector, allowing one to assess market expectations for Zentalis compared to companies already commercialized.
P/S of the market as a whole
Zentalis Pharmaceuticals is at the forefront of the fight against cancer, developing targeted therapies. These companies often have no revenue at the clinical stage, and their valuation is based on the potential of future drugs. This chart, which reflects the average real revenue estimate for the market, clearly highlights how biotech investments are a bet on scientific breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zentalis Pharmaceuticals
Zentalis Pharmaceuticals develops inhibitors that target fundamental pathways in cancer cell growth. This chart reflects investor expectations regarding the future success of its clinical trials. The company's valuation is closely linked to the projected revenue potential of its drugs, which could change the standard of cancer treatment.
%20P%2FS%20Zentalis%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zentalis-Pharmaceuticals&v=1772696718161 "The graph of the company's future (projected) P/S Zentalis Pharmaceuticals")
Future (projected) P/S of the market segment - Breast cancer
Zentalis Pharmaceuticals develops targeted drugs for the treatment of cancer, particularly breast cancer, striving to create more effective therapies. While in clinical trials, its value depends on the success of these developments. This chart shows the premium the market is willing to pay for Zentalis's future revenue compared to its competitors, reflecting its confidence in its scientific potential.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772696718175 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues hinges on breakthroughs in cancer treatment. Zentalis Pharmaceuticals, developing small-molecule drugs that target fundamental tumor growth mechanisms, is at the forefront of this fight. The success of its clinical trials inspires confidence in the ability of biotech to create new treatment standards and generate future revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772696718182 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is at the forefront of the fight against cancer, developing next-generation targeted therapies. As the company is in the clinical stage, its financial curve reflects revenue from strategic partnerships and key development milestones rather than commercial sales. Future revenue growth is directly dependent on the successful commercialization of its innovative oncology drugs.
Sales of companies in the market segment - Breast cancer
Zentalis Pharmaceuticals is at the forefront of the fight against cancer, developing targeted small-molecule drugs. By focusing on specific oncological targets, the company strives to create more effective treatments. This chart represents the total revenue of the entire breast cancer drug market, demonstrating the enormous potential for companies capable of delivering breakthrough therapies.
Overall market sales
Zentalis Pharmaceuticals develops small-molecule drugs for the treatment of cancer, focusing on inhibitors that stop tumor growth. The company's success depends on the results of clinical trials and investments in biotechnology. This overall economic activity chart reflects the investment climate and the market's willingness to finance long-term and risky R&D projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zentalis Pharmaceuticals
Zentalis Pharmaceuticals develops small-molecule cancer therapies, focusing on WEE1 inhibitors. The company's future depends on the success of clinical trials and potential partnerships. This graph reflects analyst revenue expectations, which are a bet on scientific breakthroughs and the commercialization of advanced cancer treatments.
%20sales%20of%20the%20company%20Zentalis%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zentalis-Pharmaceuticals&v=1772696718285 "Schedule of future (projected) sales of the company Zentalis Pharmaceuticals")
Future (projected) sales of companies in the market segment - Breast cancer
Zentalis Pharmaceuticals develops small-molecule cancer drugs, specifically WEE1 inhibitors. The company's success depends on clinical trials. This chart displays projected sales for the entire breast cancer drug segment. It allows one to assess the growth or decline potential analysts are predicting for the entire oncology industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772696718303 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for cancer treatment. Its future depends on the success of clinical trials and its ability to fund R&D. This overall economic climate impacts investment risk appetite, which directly determines the availability of capital for innovative but risky biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772696718315 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zentalis Pharmaceuticals
For Zentalis Pharmaceuticals, a biopharmaceutical company at the forefront of the fight against cancer, this metric reflects the financial side of innovation. It demonstrates how close the company is to converting potential revenue from its breakthrough drugs into sustainable results, covering the enormous costs of clinical research and development.
Market segment marginality - Breast cancer
Zentalis Pharmaceuticals is a biopharmaceutical company developing cancer treatments. At the clinical stage of development, resource efficiency is crucial. This metric allows investors to assess how efficiently the company uses its R&D capital compared to other players in the oncology sector.
Market marginality as a whole
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative small-molecule drugs for the treatment of cancer. Their success depends on the results of clinical trials. This graph, reflecting the overall health of the economy, is important for them in the context of capital availability for funding expensive R&D projects in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a biotechnology company developing small-molecule drugs for the treatment of cancer. Being in the clinical stage, its main asset is its scientific potential. This graph shows the dynamics of the team of scientists and researchers, whose growth directly reflects progress in clinical trials and the expansion of its pipeline of promising developments.
Share of the company's employees Zentalis Pharmaceuticals within the market segment - Breast cancer
Zentalis Pharmaceuticals is focusing its efforts on developing small molecules to fight cancer. This chart shows the percentage of leading scientists and clinicians the company attracts in this highly specialized area of oncology. Its team is its greatest asset in the race to develop new, more effective treatments.
Number of employees in the market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for the treatment of cancer, particularly breast cancer. This chart reflects overall employment in the oncology research sector. Its growth illustrates the intensity of the race for new therapies and the intense competition for talented scientists, in which Zentalis is participating.
Number of employees in the market as a whole
Zentalis Pharmaceuticals is a company at the forefront of the fight against cancer. Biotech companies like these are engines of innovation, requiring the best scientists and clinicians. This chart, reflecting overall employment, also indirectly reflects the health of research-intensive sectors, where every new hire is an investment in the future of medicine and saving lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals is a biotech company focused on developing small-molecule drugs for cancer treatment. This chart shows that the market values each company employee very highly. This metric is typical for innovative R&D companies, where the team's intellectual capital and scientific breakthroughs generate the bulk of its value, rather than physical assets.
%20of%20the%20company%20Zentalis%20Pharmaceuticals%20(ZNTL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zentalis-Pharmaceuticals-ZNTL&v=1772696718580 "Chart of market capitalization per employee (in thousands of dollars) of the company Zentalis Pharmaceuticals (ZNTL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech company focused on developing innovative cancer treatments. In this sector, value is created not by the number of employees, but by the strength of intellectual property. This chart shows how the market values their R&D potential per team member, reflecting investor expectations for future breakthroughs.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772696718606 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology. Its value is almost entirely dependent on the potential of its investigational drugs and its intellectual property. This metric vividly illustrates the economics of biotech, where a small team of highly skilled scientists creates developments valued in the hundreds of millions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772696718666 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals is a biotech R&D company focused on developing small molecules for cancer treatment. Their business is not sales, but science. This chart shows their net financial performance. At the clinical stage, it reflects how much the company invests (or loses) per highly qualified scientist and employee working on future drugs.
%20Chart%20Zentalis%20Pharmaceuticals%20(ZNTL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zentalis-Pharmaceuticals-ZNTL&v=1772696718694 "Company Profit Per Employee (in thousands of dollars) Chart Zentalis Pharmaceuticals (ZNTL)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
For Zentalis, a clinical-stage biopharmaceutical company, this graph is a benchmark for the future. Currently, all resources are focused on breast cancer R&D, so profitability is negative. This metric will become relevant if their drug candidates successfully enter the market and the small team is able to monetize their intellectual property.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772696718725 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Zentalis Pharmaceuticals (ZNTL) is a biotech company focused on cancer drug development. Their business is pure R&D, searching for new molecules. This graph reflects the efficiency of human capital utilization. For Zentalis, which employs highly skilled scientists rather than salespeople, this metric will be negative until their drugs reach the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772696718790 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zentalis Pharmaceuticals (ZNTL)
For Zentalis Pharmaceuticals, which develops targeted cancer drugs, this chart reflects the effectiveness of its scientific and commercial strategy. High revenue per employee will indicate the successful launch of innovative drugs capable of generating significant revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zentalis-Pharmaceuticals-ZNTL&v=1772696718846 "Sales chart per company employee Zentalis Pharmaceuticals (ZNTL)")
Sales per employee in the market segment - Breast cancer
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing cancer treatments. Their business is science-intensive R&D, and their staff consists of highly qualified scientists and clinicians. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive Zentalis' R&D team is in monetizing its developments compared to other biotech companies.
Sales per employee for the market as a whole
Zentalis (ZNTL) is a clinical-stage biopharmaceutical company developing cancer treatments. Currently, its staff consists primarily of scientists and researchers. This metric is particularly interesting for ZNTL: it reflects the transition from pure R&D to commercialization. Until the drug is approved, this value is close to zero. An increase in this chart will signal initial sales.
Short shares by company, segment and market as a whole
Shares shorted by company Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals is an oncology biotech focused on developing WEE1 inhibitors. Like many clinical-stage companies, its future hinges on a "binary event"—the success or failure of clinical trials. This chart shows how many investors are betting on its scientific platform failing to prove effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zentalis-Pharmaceuticals-ZNTL&v=1772696718931 "Short Shares Chart for the Company Zentalis Pharmaceuticals (ZNTL)")
Shares shorted by market segment - Breast cancer
Zentalis (ZNTL) is a biopharmaceutical company focused on developing small-molecule drugs for the treatment of cancer, including breast cancer. Their future depends on the success of clinical trials. This chart shows the aggregate short positions across the entire oncology biotech sector. It reflects the general investor skepticism regarding the high risk and cost of development in this area.
Shares shorted by the overall market
Zentalis (ZNTL) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like ZNTL in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zentalis Pharmaceuticals (ZNTL)
Zentalis is a biotech company working in the competitive field of oncology (including breast cancer). This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive trial data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zentalis-Pharmaceuticals-ZNTL&v=1772696718966 "RSI 14 indicator chart for the company's stock Zentalis Pharmaceuticals (ZNTL)")
RSI 14 Market Segment - Breast cancer
Zentalis (ZNTL) is a sniper in oncology. They are developing targeted therapies (WEE1, BCL-2) for the treatment of breast cancer and other tumors. The breast cancer (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It is vital to understand: is ZNTL's growth due to their R&D or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Zentalis Pharmaceuticals (ZNTL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZNTL (Zentalis Pharmaceuticals)
Zentalis Pharmaceuticals is a biotech company developing targeted cancer therapies, including WEE1 (ZN-c3) inhibitors, particularly for breast cancer. This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential of their drugs in various oncology combinations.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZNTL-Zentalis-Pharmaceuticals&v=1772696719017 "A chart showing analyst consensus forecasts for the expected stock price. ZNTL (Zentalis Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ZNTL (Zentalis Pharmaceuticals)
Zentalis is a biotech company focused on developing a new class of small-molecule drugs (WEE1 inhibitors) for the treatment of cancer. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this specific oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZNTL-Zentalis-Pharmaceuticals&v=1772696719040 "A chart showing the difference between the consensus forecast and the actual stock price. ZNTL (Zentalis Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
Zentalis Pharmaceuticals is a biotech company developing a new generation of targeted oncology drugs (including WEE1 inhibitors) for cancer treatment. This chart reflects overall expectations for the breast cancer sector, demonstrating whether experts believe in the success of new R&D approaches in oncology.
Analysts' consensus forecast for the overall market share price
Zentalis (ZNTL) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, including breast cancer. This chart shows the overall market risk appetite and serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zentalis Pharmaceuticals
Zentalis (ZNTL) is a clinical-stage biotech focused on precision oncology. Their signature drug is WEE1 inhibitors, a new class of drugs they hope will be effective against breast cancer and other tumors. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their competition.
AKIMA Market Segment Index - Breast cancer
Zentalis Pharmaceuticals is a clinical-stage company developing targeted therapies for cancer, including WEE1 inhibitors, with a particular focus on breast cancer. This chart shows the average oncology sector index, allowing investors to assess how Zentalis's scientific approach compares to the industry average.
The AKIM Index for the overall market
Zentalis Pharmaceuticals is an oncology company developing small molecules for cancer treatment (Wee1 inhibitors). This chart, reflecting the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this clinical development that is overcoming regulatory hurdles.
